Oramed Pharmaceuticals Inc. Share Price Deutsche Boerse AG

OJU1

US68403P2039

Biotechnology & Medical Research

Real-time Estimate Tradegate 07:06:54 01/09/2026 BST			5-day change	1st Jan Change
4.328 ^EUR	+1.12%		+4.80%	+76.41%

08-31	Lifeward Names Josh Hexter as Interim CEO and Rami Aviram as CFO	MT
08-10	Oramed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Valuation : Oramed Pharmaceuticals Inc.

Market Cap	209M 180M 169M 154M 289M 19.87B 292M 2B 778M 10.08B 784M 767M 33.36B	P/E 2026 *	1.12x	P/E 2027 *	-
Enterprise Value	209M 180M 169M 154M 289M 19.87B 292M 2B 778M 10.08B 784M 767M 33.36B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	82.35%	Yield 2026 *	-	Yield 2027 *	-

* Estimated data More valuation ratios

Chart: Oramed Pharmaceuticals Inc.

Dynamic Chart

Latest news : Oramed Pharmaceuticals Inc.

08-31	Lifeward Names Josh Hexter as Interim CEO and Rami Aviram as CFO	MT
08-10	Oramed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-08	Lifeward Ltd. announced that it has received $11.16 million in funding from Oramed Pharmaceuticals Inc.	CI
06-29	Lifeward Ltd. announced that it expects to receive $11.16 million in funding from Oramed Pharmaceuticals Inc.	CI
06-29	Oramed Pharmaceuticals Inc.(NasdaqCM:ORMP) added to Russell 2000 Index	CI
06-29	Oramed Pharmaceuticals Inc.(NasdaqCM:ORMP) added to Russell 2000 Value Benchmark	CI
06-29	Oramed Pharmaceuticals Inc.(NasdaqCM:ORMP) added to Russell 3000E Index	CI
06-29	Oramed Pharmaceuticals Inc.(NasdaqCM:ORMP) added to Russell 2000 Value-Defensive Index	CI
06-28	Oramed Pharmaceuticals Inc.(NasdaqCM:ORMP) added to Russell 3000E Value Benchmark	CI
06-28	Oramed Pharmaceuticals Inc.(NasdaqCM:ORMP) added to Russell 2000 Dynamic Index	CI
06-28	Oramed Pharmaceuticals Inc.(NasdaqCM:ORMP) added to Russell 2000 Defensive Index	CI
06-28	Oramed Pharmaceuticals Inc.(NasdaqCM:ORMP) added to Russell 3000 Value Benchmark	CI
06-28	Oramed Pharmaceuticals Inc.(NasdaqCM:ORMP) added to Russell Small Cap Completeness Index	CI

More news

Analysts' recommendations : Oramed Pharmaceuticals Inc.

17/05/23	Canaccord Genuity Adjusts Price Target on Oramed Pharmaceuticals to $2 From $3, Maintains Hold Rating	MT
17/01/23	HC Wainwright Downgrades Oramed Pharmaceuticals to Neutral From Buy	MT
12/01/23	Cantor Fitzgerald Downgrades Oramed Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $5 From $20	MT
12/01/23	Canaccord Genuity Downgrades Oramed Pharmaceuticals to Hold From Buy, Adjusts Price Target to $3 From $30	MT
16/05/22	Aegis Capital Adjusts Price Target for Oramed Pharmaceuticals to $30 From $35, Maintains Buy Rating	MT

More recommendations

Press Releases : Oramed Pharmaceuticals Inc.

08-10	Oramed: Q2 Earnings Snapshot	AQ
06-25	Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet	PR
06-17	Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes	PR
05-19	Oramed: Q1 Earnings Snapshot	AQ
03-26	Oramed: Q4 Earnings Snapshot	AQ

More press releases

News in other languages : Oramed Pharmaceuticals Inc.

22/03/21	Premas Biotech : et Oramed annoncent un vaccin candidat oral contre la COVID-19 qui produit des anticorps après une seule dose
30/11/15	Amazon : Les valeurs à suivre sur les marchés américains
30/11/15	USA-Les valeurs à suivre à Wall Street

More news

Managers and Directors : Oramed Pharmaceuticals Inc.

Manager	Title	Age	Since
Miriam Kidron CTO	Chief Tech/Sci/R&D Officer	85	28/02/2006
Nadav Kidron CEO	Chief Executive Officer	52	07/03/2006
Avraham Gabay DFI	Director of Finance/CFO	41	31/05/2019

Director	Title	Age	Since
Nadav Kidron CHM	Chairman	52	29/06/2022
Miriam Kidron BRD	Director/Board Member	85	11/04/2002
Arie Mayer BRD	Director/Board Member	70	04/12/2019

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ORAMED PHARMACEUTICALS INC.	+1.12%	+4.80%	-	-	209M
LONZA GROUP AG	-1.23%	-1.91%	+0.98%	+17.94%	49.81B
REVOLUTION MEDICINES, INC.	-1.11%	-2.84%	+420.04%	+505.15%	44.06B
IQVIA HOLDINGS INC.	-0.21%	+0.37%	+36.88%	+17.32%	42.99B
BEONE MEDICINES AG	-1.95%	-3.33%	+8.29%	+73.25%	40.88B
CELLTRION, INC.	-0.94%	-1.77%	+18.34%	+46.84%	33.11B
MEDPACE HOLDINGS, INC.	-1.11%	-4.20%	+25.49%	+119.78%	16.58B
ASCENDIS PHARMA A/S	+6.10%	+4.40%	-	-	17.27B
EUROFINS SCIENTIFIC SE	+0.25%	-0.98%	+11.91%	+27.62%	14.63B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.12%	-3.46%	+76.50%	+39.37%	13.76B
Average	-0.02%	-1.37%	+74.80%	+105.91%	30.34B
Weighted average by Cap.	-0.57%	-1.50%	+88.88%	+122.63%

See all sector performances

Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.

Employees

Sector

Biotechnology & Medical Research

More about the company